With a Costly Cancer Drug, the Dose Appears Optional
The American biotechnology company Genentech said Thursday that a low dose of its cancer drug Avastin worked just as well as a more expensive high dose in a clinical trial of patients with lung cancer.
This entry was posted on Friday, February 23rd, 2007 at 9:42 am and is filed under Research, Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.